The combination therapy of 'Padcev+Keytruda,' which is expected to bring a paradigm shift to bladder cancer treatment, will soon land in South Korea.

The Ministry of Food and Drug Safety (MFDS) is reviewing the expansion of indication for Astellas Korea's Padcev (enfortumab), an antibody-drug conjugate (ADC), in combination with Keytruda (pembrolizumab), a PD-1 inhibitor that is used in immunotherapy for cancer, as a first-line treatment of urothelial cancer locally advanced or metastatic urothelial carcinoma (la/mUC). The official approval is expected soon.

The combination therapy of these drugs for urothelial cancer gained attention after the presentation of its Phase 3 EV-302/KEYNOTE-